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Metabolic reprogramming: the emerging




Tumor tissue is composed of cancer cells and surrounding stromal cells with diverse genetic/epigenetic
backgrounds, a situation known as intra-tumoral heterogeneity. Cancer cells are surrounded by a totally different
microenvironment than that of normal cells; consequently, tumor cells must exhibit rapidly adaptive responses to
hypoxia and hypo-nutrient conditions. This phenomenon of changes of tumor cellular bioenergetics, called
“metabolic reprogramming”, has been recognized as one of 10 hallmarks of cancer. Metabolic reprogramming is
required for both malignant transformation and tumor development, including invasion and metastasis. Although
the Warburg effect has been widely accepted as a common feature of metabolic reprogramming, accumulating
evidence has revealed that tumor cells depend on mitochondrial metabolism as well as aerobic glycolysis.
Remarkably, cancer-associated fibroblasts in tumor stroma tend to activate both glycolysis and autophagy in
contrast to neighboring cancer cells, which leads to a reverse Warburg effect. Heterogeneity of monocarboxylate
transporter expression reflects cellular metabolic heterogeneity with respect to the production and uptake of
lactate. In tumor tissue, metabolic heterogeneity induces metabolic symbiosis, which is responsible for adaptation
to drastic changes in the nutrient microenvironment resulting from chemotherapy. In addition, metabolic
heterogeneity is responsible for the failure to induce the same therapeutic effect against cancer cells as a whole. In
particular, cancer stem cells exhibit several biological features responsible for resistance to conventional anti-tumor
therapies. Consequently, cancer stem cells tend to form minimal residual disease after chemotherapy and exhibit
metastatic potential with additional metabolic reprogramming. This type of altered metabolic reprogramming leads
to adaptive/acquired resistance to anti-tumor therapy. Collectively, complex and dynamic metabolic reprogramming
should be regarded as a reflection of the “robustness” of tumor cells against unfavorable conditions. This review
focuses on the concept of metabolic reprogramming in heterogeneous tumor tissue, and further emphasizes the
importance of developing novel therapeutic strategies based on drug repositioning.
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Introduction
Tumor tissue consists of a heterogeneous cellular popula-
tion. Stromal cells such as neurons, vascular endothelial
cells, fibroblasts, and macrophages in cancer tissue drive
chemotherapy resistance [1] as well as tumor survival and
progression [2, 3]. Even in pure populations of tumor cells,
heterogeneity is present as a result of genetic mutation
and epigenetic modulations. This cellular heterogeneity
can be explained by a hierarchical model, in which cancer
stem-like cells (CSCs) can provide transient amplifying
cells and differentiated non-CSCs involved in establishing
the tumor tissue [4, 5]. CSCs possess several biological fea-
tures of “stemness”, a combination of phenotypes including
plasticity in the transition between quiescent (G0 phase)
and proliferative states [6] and resistance to redox stress
and chemotherapeutic agents [7, 8]. Importantly, accumu-
lating evidence suggests that metabolic reprogramming is
crucial in order for CSCs to maintain unlimited self-
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renewal potential and hyper-adaptation to drastic changes
in the tumor microenvironment [9–11].
Intra-tumoral heterogeneity due to the presence of CSCs
is primarily responsible for our inability to induce the same
therapeutic effect among cancer cells as a whole [12, 13].
CSCs are very likely to contribute to the formation of min-
imal residual disease (MRD) [1]. The term ‘MRD’ is most
often used in the context of hematological malignant disor-
ders [14], but the underlying concept is quite convenient in
discussion of clinically undetectable resistant clones after
conventional anti-tumor therapies [1]. Thus, MRD is ex-
pected to contribute prominently to latent relapse and dis-
tant metastasis (Fig. 1).
Aberrant proliferation of cancer cells is supported by en-
hanced adaptation to nutrient microenvironment mediated
by alterations in energy metabolism. Consequently, meta-
bolic reprogramming is believed to be one of the hallmarks
of tumor cells in parallel with genomic instability, tumor-
provoking chronic inflammation, escape from the immune
system, etc. [5]. Although aerobic glycolysis, termed the
Warburg effect, is a characteristic metabolic feature of can-
cer cells [15, 16], recent investigations revealed that other
metabolic features, in particular, the reverse Warburg effect
[17, 18], metabolic symbiosis [19, 20], and addiction to
glutamine metabolism [21, 22], create challenges for anti-
cancer treatment due to adaptive or acquired chemoresis-
tance. This review article focuses on the relationship
between metabolic reprogramming and tumor hetero-
geneity, as well as on the development of promising
therapeutic strategies by drug repositioning targeting
metabolic reprogramming.
Conventional Warburg effect and emerging concepts
In 1924, Otto Warburg discovered that tumor cells
tend to produce large amounts of lactate from glucose,
regardless of the available oxygen level [15, 16]. This
situation is similar to anaerobic glycolysis, implying
that oxidative phosphorylation (OXPHOS) is replaced
by glycolysis in normal differentiated cells under hyp-
oxia [23, 24]. However, cancer cells appear to engage in
glycolytic metabolism before they are exposed to hypoxic
conditions [15, 16]. OXPHOS in mitochondria generates as
many as 36 mol ATP from 1 mol glucose, whereas the con-
version of glucose to pyruvate or lactate produces only 2 or
4 mol ATP, respectively [25, 26]. It remains unclear why
cancer cells largely depend on this “inefficient” metabolic
pathway, even when enough oxygen is available [27, 28]. In
striking contrast to normal cells, cancer cells preferentially
uptake and convert glucose into lactate even in the pres-
ence of sufficient oxygen [29]. This seemingly “inefficient”
metabolic characteristic relies largely on aberrant up-
regulation of GLUT1, a glucose transporters abun-
dantly expressed in cancer cells [30, 31], although one
contradictory study reported that GLUT1 is not neces-
sarily involved in the Warburg effect depending on the
degree of tumor invasiveness [32]. Inefficient ATP syn-
thesis becomes an obstacle for cancer cells only when
their energy resources are scarce. However, this is not
the case in proliferating cancer cells with aberrant
angiogenesis [29]. Tumor cells finely regulate ATP syn-
thesis by regulating substrate uptake, as well as en-
zymes related to glycolysis, which enables them adapt
to the nutrient microenvironment [33]. Moreover, the
regulation of adenosine monophosphate-activated pro-
tein kinase (AMPK) signal transduction, a sensor of en-
ergy status, is intimately connected to the Warburg
effect, one form of metabolic reprogramming of cancer
cells [34, 35]. Indeed, genetic ablation of AMPK acti-
vates mammalian target of rapamycin (mTOR) signal
with ectopic expression of hypoxia-inducible factor-1
alpha (HIF-1 alpha), resulting in rapid cellular prolifera-
tion accompanied by activation of aerobic glycolysis








Fig. 1 Cancer stem cells and MRD formation. Heterogeneous tumor tissue with combined-modality therapy leads to the formation of MRD, which
is clinically undetectable. Transiently reduced heterogeneity is observed in MRD, which is enriched in CSCs. Relapse or metastasis results in re-acquisition
of a heterogeneous population that is more potentially aggressive in terms of its degree of “stemness”
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[35]. This strongly suggests the importance of cancer
metabolic reprogramming in maintaining the interaction
between the oxygen-sensing transcription factor and the
nutrient-sensing signal pathway.
Metabolic reprogramming in response to chemotherapy
Tumor heterogeneity in regard to mitochondrial metab-
olism, in seeming contradiction to the Warburg effect, is
considered to induce the diversity in activated metabolic
pathways [36] (Fig. 2). Notably, MRD in several kinds of
cancers is enriched in CSCs, leading to intra-tumoral
heterogeneity and poor prognosis [1, 9, 10, 37]. Non-
CSCs of bladder cancer, for instance, release prostaglan-
din E2 (PGE2) when they undergo apoptosis during the
course of chemotherapy. PGE2 promotes the awakening
of dormant G0-phased CSCs into the proliferative state
[9]. Given that PGE2-mediated metabolic activation in
mitochondria has been demonstrated in non-malignant
cells [38], it is possible that activated CSCs undergo
altered metabolic reprogramming (Fig. 3). Similarly, the
survivors after transient depletion of a driver oncogene
(i.e., activated mutant KRASG12D in pancreatic cancer)
tend to depend heavily on OXPHOS in mitochondria
rather than aerobic glycolysis. Comprehensive analysis of
metabolic pathways of survivors after chemotherapy
revealed the prominent expression of genes that regulate
mitochondrial function, autophagy and lysosome deg-
radation activity, as well as a strong reliance on mito-
chondrial respiration and diminished dependence on the
Warburg effect [10]. Autophagy is a metabolic-recycling
pathway involving proteasome-independent degradation of
cellular components (e.g., old and dysfunctional mitochon-
dria), which is partially responsible for cancer chemoresis-
tance [39].
Furthermore, malignant melanoma cells that survive and
proliferate after treatment with mutant BRAF (V600E)
inhibitor tend to exhibit relative dependence on mito-
chondrial metabolism [11]. Because BRAF suppresses oxi-
dative phosphorylation (OXPHOS), MRD cells up-regulate
proliferator-activated receptor-gamma coactivator-1 (PG
C1-alpha). The BRAF (V600E)-MITF-PGC1-alpha axis
promotes the biogenesis of mitochondria and causes BR
AF-mutant melanoma cells to become addicted to mito-
chondrial metabolism [11]. Because histone H3 lysine 4
(H3K4)-demethylase JARID1B-highly expressing mel-
anoma cells proliferate slowly and are highly dependent
on mitochondrial metabolism [11, 40], chemotherapy-
induced metabolic reprogramming in tumor tissue is
likely to be responsible for the enrichment of CSCs
in MRD.
Metabolic interaction driven by tumor heterogeneity
Initially, the concept of Warburg effect was believed to
be confined to cancer cells. More recently, the emerging
concept of the “reverse Warburg effect”, however, has
attracted considerable attention. Tumor cell-derived re-
active oxygen species (ROS) decrease the expression of
caveolin-1 in cancer-associated fibroblasts (CAFs). CAFs
are the major component of tumor stroma, and as such
they express alpha-smooth muscle actin (alpha-SMA)
and are widely recognized to drive tumor progression
and metastasis [41]. Loss of caveolin-1 in CAFs re-
sults in elevated ROS levels, which in turn stabilize
HIF-1 alpha [17, 42]. In brief, cancer cells create
“pseudo-hypoxic” conditions for fibroblasts. Because the
transcription factor HIF-1 alpha promotes glycolysis and
provides tumor cells with lactate and glutamate, elevated
production of ROS in cancer cells indirectly induces







Tumor Cellular Heterogeneity in Metabolism 
Acidity (low pH)
Proliferation 
Fig. 2 Tumor heterogeneity in metabolism. The degree of addiction to glucose or glutamate differs among various types of cancer cells. Tumor
cells robustly importing glucose via the GLUT1 transporter are responsible for the high intensity of FDG-PET in the clinical settings. Cancer cells
that express high levels of GLUT1 also induce a low-pH acidic tumor microenvironment, thereby increasing the invasive potential of tumors
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acid (TCA) cycle in mitochondria. CAFs consume more
glucose and secrete more lactate than normal fibroblasts.
Furthermore, CAFs depend significantly on autophagy,
and the activation of autophagy in tumor stroma leads to
chemoresistance [18, 42] (Fig. 4).
As mentioned above, fibroblasts surrounding epithelial
cancer cells undergo metabolic reprogramming resem-
bling the phenotype associated with the Warburg effect.
Metabolic symbiosis between epithelial cancer cells and
CAFs requires that each cell express a different subtype
of monocarboxylate transporter (MCT). Epithelial cancer
cells express MCT1, which contributes to uptake of lac-
tate provided by caveolin1-null CAFs expressing MCT4
[17, 43]. Tumor cells synthesize pyruvate from lactate,
providing the TCA cycle with an intermediate metabolite.
Notably, an extracellular space rich in lactate reflects
acidic conditions, which in turn lead to the formation of
pseudo-hypoxic conditions.
It should be emphasized, however, that this reverse
Warburg effect is not necessarily present in all tumor
Proliferating CSCs with 
activated mitochondria





Fig. 3 Iatrogenic activation of CSCs with altered metabolic reprogramming. Non-CSCs are susceptible to chemotherapy and undergo apoptosis.
Released PGE2 awakens the dormant CSCs localized in the niche. Proliferating CSCs are likely to exhibit additional metabolic reprogramming,












Fig. 4 Interaction of caveolin 1-deficient CAFs with tumor cells. Cancer cells induce a pseudo-hypoxic microenvironment rich in ROS derived from
metabolic reprogramming. By contrast, CAFs negative for caveolin 1 provide tumor cells with lactate, pyruvate, and ketone bodies. Notably,
although cancer cells depend heavily on mitochondrial metabolism, CAFs exhibit the Warburg effect and activation of the autophagic pathway
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types. Tumors expressing high levels of MCT4 or mesen-
chymal phenotype do not tend to exhibit the reverse
Warburg phenomenon. Instead, cancer cells exhibit hier-
archical metabolic heterogeneity: MCT4-expressing tumor
cells perform glycolysis and secrete lactate via MCT4,
whereas MCT1-expressing cells import lactate via MCT1
and perform OXPHOS. In addition, the amount of glucose
uptake is lower in MCT1-positive cancer cells than in
MCT4-positive cells [19, 20] (Fig. 5). This metabolic het-
erogeneity is referred to as metabolic symbiosis, and this
kind of lactate shuttle is also observed between neurons
and astrocytes in the normal brain tissue [44]. It is notable
that normal and cancerous tissues share finely regulated
mechanisms of metabolic symbiosis.
Cancer stem-like cells in metabolic symbiosis
Importantly, well-oxygenated/aerobic cancer cells ex-
pressing high levels of MCT1 efficiently produce meta-
bolic intermediates, as well as ATP, by utilizing lactate
derived from hypoxic/glycolytic cells expressing high
levels of MCT4. Redox stress is a major hallmark of can-
cer tissues that drives robust metabolism in adjacent
proliferating MCT1-positive cancer cells, which are rich
in mitochondria, mediated by the paracrine transfer of
mitochondrial fuels such as lactate, pyruvate, and ketone
bodies [19, 20] (Figs. 4 and 5).
Most importantly, genotoxic stress due to chemother-
apy or irradiation, which increase ROS levels, promotes
a CSC-like phenotype [45–47]. Because CSCs exhibit a
rapidly proliferating and poorly differentiated phenotype,
MCT1-positive cancer cells are likely to harbor stem-
like phenotypes in heterogeneous populations of tumor
cells. After all, activated mitochondrial metabolism pro-
duces enough energy not only for self-renewal by prolifer-
ation but also for invasion/distant metastasis, both of
which are activated in CSCs.
Thus, the pharmacological blockage of MCT1 is useful
for the treatment of cancer. MCT1 inhibition disrupts
metabolic symbiosis, and MCT1-positive aerobic cancer
cells can no longer uptake lactate [20], which suggests
that MCT1-positive CSCs play a fundamental role in
maintaining the hierarchy in tumor cellular society, in
contrast to MCT4-positive cells (Fig. 5).
Acquisition of stem-like and malignant phenotypes with
metabolic reprogramming
The cooperation of amino acid transporters is necessary
for cancer cells to undergo metabolic reprogramming
and maintain stem-like phenotypes. For example, triple-
negative breast cancer (TNBC) cells, which lack estrogen
receptor, progesterone receptor, and the tyrosine kinase
receptor HER2, exhibit addiction to glutamine metabol-
ism due to coordination between the xCT and ASCT2
amino acid transporters [48, 49]: xCT uptakes cystine in
exchange for glutamine, for use in GSH synthesis [7],
























Fig. 5 Metabolic symbiosis between oxidative/aerobic tumor cells and hypoxic/glycolytic cells. Tumor heterogeneity induces a lactate shuttle
between hypoxic and oxidative cancer cells. While MCT4-positive hypoxic cells contribute to formation of an acidic microenvironment by aerobic
glycolysis and secretion of lactate, MCT1-expressing oxidative cells utilize lactate as a substrate of the TCA cycle, and consequently exhibit stem-like
characteristics. Notably, in contrast with MCT1-positive cancer cells, glucose uptake is robust in MCT4-expressing cells
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manner [50]. Glutamine is simultaneously imported via
ASCT2 transporter and exported in exchange for leucine
via the LAT1/4F2 (CD98 heavy chain) antiporter [48].
The glutamine uptake pathway contributes to the synthesis
of alpha-KG, promoting the TCA cycle in mitochondria, as
well as glutamate, thereby promoting synthesis of nucleo-
tides required for cellular proliferation [48] (Fig. 6). Thus,
metabolic reprogramming, which is orchestrated by the
elevated expression and interaction of amino acid trans-
porters, contributes to the activation of glutamine meta-
bolic reprogramming and protects tumor cells against
accumulation of oxidative stress mediated by cystine meta-
bolic reprogramming.
Remarkably, circulating tumor cells (CTCs) that have
undergone metabolic reprogramming provide them-
selves with a microenvironment that is favorable for
colonization and distant metastasis. Recent work showed
that CTCs derived from colon adenocarcinoma and
positive for CD110, the thrombopoietin receptor, can
home to the pre-metastatic niche and colonize meta-
static hepatic tissue due to elevated lysine catabolism
[51, 52]. Lysine degradation provides CD110-positive
CTCs with glutamate and acetyl-CoA, which contrib-
utes to the synthesis of anti-oxidant GSH and p300-
dependent LRP6 acetylation, respectively [52, 53].
This metabolic reprogramming promotes the meta-
static potential of CTCs via a reduction in ROS levels, ele-
vation of self-renewal potential, and activation of the
Wnt/beta-catenin signal pathway [52]. Thus, CTCs resem-
ble CSCs during the process of metastasis, at least in
terms of the ‘education’ of the pre-metastatic niche. Most
importantly, this metastatic phenotype is supported by
lysine metabolic reprogramming.
A subpopulation of cancer cells that depend heavily on
aerobic glycolysis robustly uptakes and consumes glucose,
whereas another subpopulation engages in OXPHOS and
glutaminolysis with activated mitochondrial metabolism.
The efficiency of lactate production in the former (MCT4-
positive) subpopulation is much higher than in the latter
(MCT1-positive) subpopulation, which relies on OXPHOS
and glutamine-derived TCA cycle in the mitochondria [54]
(Fig. 5). Thus, tumor cells tend to decrease microenviron-
mental pH via elevated lactate secretion. The acidic tumor
microenvironment induces expression of matrix metallo-
proteinases (MMPs), especially MMP-2 and MMP-9 [55].
Thus, metabolic reprogramming remarkably enhances the
invasion and metastatic potentials of cancer cells.
Activation of glutamine metabolism driven by oncogene
addiction
Mitochondria plays a much more important role in cancer
metabolism than previously expected, and glutaminolysis
is the most common metabolic pathway regulated in this
organelle [56]. Glutaminolysis is the series of biochemical
reactions by which glutamine is catabolized into down-
stream metabolites, e.g., alpha-ketoglutarate (alpha-KG)
and glutamate. Via the TCA cycle, alpha-KG undergoes
catabolism to malate, which is transported into the
cytoplasm and converted to pyruvate, and then ultim-


















Fig. 6 Metabolic reprogramming of amino acids due to coordinated transporters. ASCT2/LAT1 and xCT/CD98hc transporter complexes in tumor
cells activate the mTORC1-SIRT4-GDH axis and glutathione synthesis, respectively. The former pathway promotes conversion of glutamate into
alpha-KG, a substrate of the TCA cycle, whereas the latter pathway maintains redox status
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signaling promotes glutamine anaplerosis via upregu-
lation of glutamate dehydrogenase (GDH) [57]. SIRT4
is a mitochondrial-localized member of the sirtuin
family of NAD-dependent enzymes that play funda-
mental roles in metabolism, stress response and lon-
gevity [58]. In regard to glutaminolysis, SIRT4 is a
critical negative regulator for glutamine metabolism in
mitochondria [58], which is down-regulated at the
transcriptional level when the mTOR signaling path-
way is activated [57]. Thus, mTOR inhibitors such as
rapamycin are expected to block mTORC1-SIRT4-
GDH axis, which is essential for glutaminolysis [57]
(Fig. 6).
As mentioned above, tumor tissue consists of a cellular
population that is heterogeneous in terms of dependency
on the Warburg effect and mitochondrial metabolism.
Relative to slow-cycling CSCs, proliferative cancer cells
tend to take up a great deal of glutamine, as well as glucose,
for the generation of metabolites [54]. Both aerobic
glycolysis and glutaminolysis are frequently simultan-
eously activated in malignant cancer cells [36, 59].
Seemingly paradoxically, however, some cancer cell
lines cannot survive and proliferate in the absence of
glutamine, despite the fact that glutamine is a non-
essential amino acids that can be synthesized from
glucose [60]. Glutamine is a primary substrate for the
TCA cycle and is required to maintain the redox state via
the production of nicotinamide adenine dinucleotide
phosphate (NADPH). Glutaminolysis enables cancer cells
to reduce NADP+ to NADPH, a reaction that is catalyzed
by malic enzymes. NADPH is a required electron donor
for reductive steps in lipid synthesis, nucleotide metabol-
ism, and maintenance of reduced GSH [21]. In this way,
metabolic reprogramming of glutaminolysis enables can-
cer cells to regulate redox state.
Oncogenic c-Myc mediates elevation of glutaminoly-
sis in cancer cells. c-Myc promotes both glutamine
uptake and glutamine catabolism [61]. Because of c-
Myc-mediated metabolic reprogramming, cancer cells
tend to exhibit “glutamine addiction” [48, 61]. This is
a typical example of metabolic reprogramming in can-
cer cells with oncogene-addiction [62, 63], suggesting
a potential “Achilles’ heel” of tumor cells that are
addicted to glutamine metabolism in manner that is
mediated by c-Myc.
Therapeutic strategies targeting metabolic
reprogramming
Drug repositioning (DR), screening for anti-cancer thera-
peutic effects of conventionally administered medications
for non-malignant disorders, has attracted a great deal of
attention because the safety and frequency of side effects
of these medicines have been already proven [64]. Proton
pump inhibitor (PPIs), for instance, are acid-activated pro-
drugs that inhibit H/K-ATPase expressed in gastric par-
ietal cells and are conventionally used for the treatment of
gastric ulcer [65]. PPIs have exert synergistic effects on
chemotherapy [66] by modulating the acidic microenvir-
onment [67] or down-regulating microRNAs involved in
chemotherapy resistance [68]. Other typical examples of
DR include sulfasalazine [7, 8, 69], itraconazole [70, 71],
terfenadine [72, 73], and simvastatin [74, 75] are described
in Table 1. To address their anti-tumor therapeutic effects
in clinical settings, all of those drugs are being tested in
clinical trials or xenograft experiments.
Here, we will describe in detail the potential effects of
metformin as an anti-cancer drug. DR has revealed, for
example, that metformin, an oral drug widely used to
treat type 2 diabetes mellitus (DM) [76], prevents tumor
growth and development. A large number of retrospect-
ive clinical studies also show that metformin prevents
carcinogenesis and improves clinical prognosis [77–79].
Metformin activates AMPK signal transduction, which
not only decreases insulin resistance in type 2 DM [76]
but also blocks AMPK-mediated mTOR activation even
in CSCs [77]. mTOR signals are regulated by amino-acid
transporters, characterized by the L-type amino acid
transporter 1 (LAT1; SLC7A5) and the glutamine/amino
acid transporter (ASCT2; SLC1A5) [80, 81], which is
why the AMPK-mTOR axis functions as a sensor of dy-
namic change in the nutrient/growth factor microenvir-
onment. In particular, leucine uptake via LAT1 activates
the mTOR signal pathway [81, 82] leading to poor progno-
sis [83, 84]. Because EpCAM is a functional CSC marker
that forms a complex with amino-acid transporters such as
LAT1 [82, 85], it is reasonable that the LAT1 expression
level would be positively correlated with poor prognosis
[83, 84]. Therefore, the LKB1-AMPK-mTOR axis is
orchestrated by amino-acid concentration in the tumor
microenvironment, and this axis promotes metabolic
reprogramming of cancer cells in response to the
microenvironment.
Remarkably, recent investigations have revealed that
this anti-type 2 DM drug suppresses ectonucleotide
pyrophosphatase/phosphodiesterase family member 1
(ENPP1). Consequently, metformin can inhibit the
generation of the subpopulation of cancer cells that
express high levels of ABCG2, an ATP-binding cas-
sette (ABC) transporter responsible for active drug
efflux. Mechanistically, the cytosolic domain of ENPP1
is crucial for interaction with ABCG2 at the cellular
membrane; thus ENPP1 contributes to drug resistance
by promoting the stabilization of ABCG2 [86, 87]. In
addition, metformin induces microRNA-27b-mediated sup-
pression of ENPP1, which reduces chemoresistance and
tumor seeding potential [86]. ENPP1 is widely accepted as
a cause of insulin resistance in type 2 DM [88], emphasizing
the significance of drug repositioning. Collectively, these
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observations indicate that this anti-DM agent is a promis-
ing means to attenuate the malignant behavior of cancer
cells, much like other drugs conventionally administered
for non-cancerous diseases.
Conclusions
The complex and dynamic metabolic reprogramming
should be regarded as a reflection of the “robustness”
of tumor cells against unfavorable conditions. Hyper-
adaptation due to metabolic reprogramming of cancer
cells is likely to give us a great opportunity to attack
the “shatter point” in heterogeneous tumor tissue. DR
enables us to identify “silver bullets” for the treatment
of tumor tissues in metabolically heterogeneous cell
populations. To facilitate development of novel thera-
peutic strategies, the synergistic effects of repositioned
drugs with conventional anti-cancer agents should be
evaluated in clinical trials in the near future.
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